Concord, Canada Clinical Trials

A listing of Concord, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 399 clinical trials
featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.

cataplexy
sodium oxybate
stimulant
excessive daytime sleepiness
sleep disorder
Somni Research Inc
 (8.0 away) Contact site
  • 0 views
  • 10 Jul, 2018
  • +52 other locations
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

Toronto Liver Centre
 (8.9 away)
  • 261 views
  • 19 Jul, 2021
  • +64 other locations
featured
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

atopic dermatitis
dermatitis
atopic dermatitis/eczema
YORK DERMATOLOGY CENTER
 (5.7 away) Contact site
  • 1344 views
  • 08 Dec, 2020
  • +52 other locations
featured
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments …

atopic dermatitis
eczema
atopic dermatitis/eczema
YORK DERMATOLOGY CENTER
 (5.7 away) Contact site
  • 242 views
  • 14 Dec, 2020
  • +37 other locations
featured
Digestive Health for Mature Adults 50+

Research in probiotics continues to offer opportunities for adults with digestive issues, like constipation, to seek assistance with improving their frequency and comfort.  KGK is researching the potential improvements of symptoms of occasional or daily constipation in healthy adults over 50 as a result of an investigational probiotic.Qualified participants will …

KGK Science - 19ANHK Mississauga
 (8.3 away) Contact site
  • 0 views
  • 18 Jun, 2021
  • +1 other locations
High Blood Pressure Strategy (HBPS)

This program developed by the HSFO aims at helping people of Ontario and their primary healthcare providers better diagnose, manage and control high blood pressure. The High Blood Pressure Strategy brings together healthcare providers and patients to improve the way in which family doctors, nurse practitioners and pharmacists work together …

essential hypertension
raised blood pressure
Heart and Stroke Foundation of Ontario
 (8.3 away) Contact site
  • 29 views
  • 07 Nov, 2020
  • 1 location
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Sunnybrook Research Institute ( Site 1103)
 (8.4 away) Contact site
  • 742 views
  • 26 Jun, 2021
  • +52 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

cyclin d1
acalabrutinib
rituximab
bendamustine
Research Site
 (8.4 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Sunnybrook Odette Cancer Centre
 (8.4 away) Contact site
  • 2496 views
  • 24 Jul, 2021
  • +209 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (8.4 away) Contact site
  • 211 views
  • 17 Jul, 2021
  • +362 other locations